Search results
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) The management of type 1 diabetes in adults.
29 cze 2021 · 1 Statement of intent. New and emerging medical therapies and evidence have changed the landscape for managing people with type 2 diabetes (T2D) with established cardiovascular disease (CVD) and those with cardiovascular risk factors.
28 wrz 2022 · The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019.
The Diabetes Epidemiology: COllaborative analysis of Diagnostic criteria in Europe (DECODE) study (Figure 1) reported data on dis-orders of glucose metabolism in European populations of different ages.11 The lifetime risk for DM is 30–40% and the prevalence of impaired glucose tolerance (IGT) increases linearly from about
PMDI activity timeline. RFA, request for applications. The purpose of the work underlying the ADA/EASD PMDI consensus reports, of which this is the first, is to define relevant terminology and review the current status of diagnostics and therapeutics (prevention and treatment) in diabetes, including key areas of opportunity and where further inquiry is needed (Text boxes 2–4).
31 sie 2019 · 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Francesco Cosentino.
15 lis 2023 · Based on evidence from large CVOTs, the current Guidelines provide clear recommendations on how to reduce cardiovascular risk in patients with diabetes and how to treat patients with diabetes and clinical manifestations of cardio-renal disease such as atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, and chronic kidney ...
